CD33 and acute myeloid leukemia: In drug-resistant AML cells, in addition to classical markers of resistance (efflux pumps, DNA repair systems, enzymes of the first and second phases of detoxification, etc.), various surface proteins, such as CD33 [47], nestin [48,49], latrophilin [30] and others, also change.